Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shield Therapeutics ( (GB:STX) ) just unveiled an announcement.
Shield Therapeutics reported a sharp improvement in its first-quarter 2026 performance, with group net revenues rising to $18 million and EBIT turning positive at about $2.5 million, driven by a $7.9 million milestone payment from its Chinese partner ASK and 54% year-on-year growth in U.S. ACCRUFeR sales to $9.9 million. The company highlighted strong prescription growth, modest price gains and tighter cost and working-capital management that lifted cash to $12.4 million, while cautioning that new prior authorisation rules in New York Medicaid, a key market, could weigh on sales as it pivots more heavily toward commercially insured business.
Regulatory momentum continued as China’s NMPA accepted a marketing application for ACCRUFeR and the EMA expanded FeRACCRU’s label to include children over 12, reinforcing the drug’s international growth prospects and pediatric reach. Alongside the trading update, Shield announced the planned departure of CFO Santosh Shanbhag on 1 June 2026, with CEO Anders Lundstrom stepping in as interim finance chief while the company searches for a permanent successor and ramps up investor engagement via a new online hub and webinar programme.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on STX Stock
According to Spark, TipRanks’ AI Analyst, STX is a Neutral.
The score is held back primarily by weak financial quality (ongoing losses, negative operating/free cash flow, and negative equity), partially offset by improving revenue/margins and moderately constructive price trend signals. Valuation is also constrained by loss-making status and lack of dividend support.
To see Spark’s full report on STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical group focused on treating iron deficiency and iron deficiency anemia with its oral ferric maltol product, marketed as ACCRUFeR in the U.S. and FeRACCRU in other territories. The company targets a large and growing global market through its own U.S. launch and a network of regional licensing partners across Europe, Asia-Pacific and North America.
Average Trading Volume: 1,963,661
Technical Sentiment Signal: Buy
Current Market Cap: £94.02M
Learn more about STX stock on TipRanks’ Stock Analysis page.